The Impact of COVID-19 on Human Health: Epidemiological Trends, Clinical Outcomes, and Preventive Strategies

V. D. Ambeth Kumar[1], Shashi Kant Gupta[2]
[1]Post Doc Researcher, Lincoln University College, Malaysia
[1]Department of Computer Engineering, Mizoram University, India
[2]Faculty of Engineering and Built Science, Lincoln University College-KL Malaysia
Email ID: ambeth@mzu.edu.in, raj2008enator@gmail.com

Abstract: The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has emerged as one of the most significant public health crises of the 21st century. While initial efforts focused on infection control and mitigation, it has become increasingly important to understand the broader implications of the virus on human health. This review explores the health-related impact of COVID-19, starting from its origin and transmission, through prevention strategies and diagnostic methods, to the short-term and long-term health consequences experienced by affected individuals. Particular attention is given to the variations in health outcomes among different age groups, the emergence of post-COVID syndromes, and the role and effects of vaccination programs. By presenting current data and research findings in a structured manner, this paper aims to provide a comprehensive understanding of how COVID-19 continues to influence global health outcomes.

Keywords: SARS-CoV-2, COVID-19, long COVID, public health, diagnostics, post-COVID complications, vaccination effects, age-based health impact

Introduction

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, was first identified in Wuhan, China, in late 2019. It rapidly escalated into a global health emergency due to its high transmissibility and ability to cause severe respiratory illness. By March 2020, the World Health Organization officially declared it a pandemic, highlighting its potential to overwhelm healthcare systems worldwide [1][2]. The virus is believed to have originated from zoonotic transmission, possibly involving bats and intermediate animal hosts, and quickly spread through human-to-human contact via respiratory droplets and aerosols [3][4].

The symptoms of COVID-19 vary widely, ranging from mild flu-like signs to critical respiratory distress and death. While some individuals remain asymptomatic, others may develop severe complications, particularly those with underlying conditions such as diabetes, cardiovascular disease, and compromised immunity [5][6]. Initial global responses focused on containment strategies such as lockdowns, social distancing, mask mandates, and widespread testing, which played a critical role in slowing transmission in many countries [7][8].

As the pandemic progressed, attention began to shift toward the longer-term effects of the virus on health. Many patients reported persistent symptoms even after recovering from the initial infection, leading to the identification of a condition now known as "long COVID" or "post-acute sequelae of SARS-CoV-2 infection (PASC)" [9][10]. This syndrome includes a wide range of physical, cognitive, and psychological effects that can last for weeks or months, significantly impacting quality of life, work productivity, and mental health [11][12].

Studies have shown that long COVID symptoms can occur in individuals across all age groups and even in those who experienced mild or moderate illness. Common complaints include fatigue, shortness of breath, brain fog, muscle pain, and emotional disturbances such as anxiety and depression [13][14][15]. The persistence of these symptoms has prompted increased interest in understanding the biological mechanisms of post-viral syndromes and the development of effective rehabilitation programs [16].

The health impact of COVID-19 has not been uniform. Older adults and those with comorbidities are more likely to suffer severe illness and post-COVID complications, while children and young adults generally experience milder symptoms [17][18]. However, emerging data suggests that even younger individuals may not be immune to long-term consequences, and in some cases, they develop multi-system inflammatory syndromes or cardiovascular complications following infection [19].

In response to the pandemic, unprecedented global collaboration led to the rapid development and deployment of several vaccines, many of which demonstrated high efficacy in preventing severe disease and death [20][21]. Mass vaccination campaigns began in late 2020 and have since become a cornerstone of pandemic control efforts. Vaccination has significantly reduced the burden on healthcare systems and mitigated the severity of subsequent waves of infection [22][23].

Despite these advances, challenges remain. Variants of concern have emerged that possess mutations potentially affecting transmissibility, severity, and vaccine efficacy [24]. Additionally, vaccine hesitancy, unequal distribution, and misinformation have hindered global immunization efforts [25]. As such, ongoing research, public education, and healthcare infrastructure development remain essential in managing both the current impact and future implications of the COVID-19 pandemic. This review seeks to explore the multifaceted health effects of COVID-19, with emphasis on both acute outcomes and long-term post-recovery complications.

COVID-19 IMPACT ON COUNTRIES

The global COVID-19 pandemic has significantly affected countries in Asia, with outcomes shaped by early responses, healthcare capacity, population size, and public cooperation. Asian countries varied widely in their ability to detect, manage, and mitigate the spread of the virus [34]. In general, densely populated countries with limited healthcare infrastructure faced greater challenges than wealthier nations with robust public health systems [35].

India experienced one of the largest and deadliest outbreaks. With over 45 million confirmed cases and more than 530,000 deaths, the country's second wave overwhelmed hospitals and cremation grounds [36]. Shortages in oxygen supply, ICU beds, and critical care resources highlighted systemic vulnerabilities. However, the country's massive vaccination drive, producing and administering millions of doses, later helped reduce the spread and severity of subsequent waves [37].

China, where the outbreak began, adopted a strict "Zero-COVID" policy involving lockdowns, contact tracing, and mass testing [38]. Although controversial, these strategies initially succeeded in keeping case and death numbers low. However, by late 2022, large outbreaks led to policy shifts, with the government ending mass lockdowns and focusing on vaccination and hospital preparedness [39]. Officially, China reported relatively low fatalities, though some analysts suggest underreporting [40].

Indonesia and the Philippines struggled with high transmission rates and limited healthcare access. Indonesia, the most affected Southeast Asian country, reported over 6.7 million cases and 162,000 deaths [41]. Vaccine hesitancy and logistical hurdles in archipelagic geography hindered the initial response. The Philippines also faced surges in densely populated urban centers like Manila, with limited ICU capacity and late vaccine rollout contributing to high fatality rates [42].

Japan and South Korea, despite their large urban populations, managed the pandemic effectively. South Korea's aggressive testing, digital contact tracing, and public compliance helped keep death rates relatively low [43]. Japan, while slower in its initial vaccination rollout, maintained one of the highest elder vaccination rates, minimizing fatalities during later waves [44]. Public health measures such as mask-wearing and hygiene were widely adopted [45].

In countries like Pakistan and Bangladesh, low testing rates and limited medical infrastructure complicated the tracking and treatment of cases [46]. Pakistan reported around 1.6 million cases and 30,000 deaths, though real numbers may be higher. Bangladesh similarly faced challenges in diagnostics and ICU availability. Despite limited resources, international aid and regional vaccine partnerships helped improve outcomes over time [47].

Vietnam, initially lauded for its containment success through rapid border closures and strict quarantine policies, saw an explosion of cases in later stages due to Delta and Omicron variants [48]. By late 2023, the country had over 11.5 million cases and 44,000 deaths. Public fatigue and economic strain led to a relaxation of restrictions, shifting focus to vaccination and outpatient care [49].

Iran, which faced severe waves early in the pandemic, suffered from economic sanctions that limited medical supplies. The healthcare system became overwhelmed, and with over 145,000 deaths, Iran recorded one of the highest fatality rates in the region [50]. Despite this, domestic vaccine production and government campaigns helped slow transmission in later stages.

Malaysia recorded over 5 million confirmed COVID-19 cases and more than 37,000 deaths by the end of 2023. The country implemented multiple movement control orders, nationwide lockdowns, and extensive vaccination drives [51]. Its response, while initially criticized for inconsistency, was later praised for achieving high vaccine coverage. Malaysia's healthcare system experienced significant strain during peak waves, especially in the Klang Valley region.

Singapore stood out for its highly efficient and technologically advanced pandemic management. With around 2.5 million confirmed cases and approximately 1,900 deaths, it had one of the lowest COVID-19 fatality rates in the world [52]. The government implemented proactive mass testing, contact tracing, quarantine facilities, and rapid vaccination. High trust in public health authorities and strict enforcement helped maintain order. Singapore's pandemic response is considered a model for densely populated, urbanized nations [53].

Table 1 – COVID-19 Impact Summary

Country	**Confirmed Cases**	**Deaths**	**Major Factors & Response Summary**
India	45	531	Severe second wave; overwhelmed health system; massive vaccination later helped
China	3.2	22	Strict Zero-COVID policy; mass lockdowns and testing; late policy shift

Indonesia	6.7	162	High fatality; logistical challenges; vaccine hesitancy in early stages
Philippines	4.1	67	ICU shortages; urban surge; slow early vaccine rollout
Japan	33.4	74	Elderly vaccination success; public compliance high
South Korea	30.5	35	Strong digital tracing, testing; well-prepared public health infrastructure
Pakistan	1.6	30	Low testing; underreported deaths; international support improved outcomes
Bangladesh	2.1	29	ICU shortages; improved outcomes with aid and vaccine partnerships
Vietnam	11.5	44	Early success with containment; later surge from Delta/Omicron variants
Iran	7.6	145	Economic sanctions hurt response; domestic vaccine production helped later
Malaysia	5	37	Movement control orders; high vaccine coverage in later phases
Singapore	2.5	1.9	Tech-driven pandemic response; low fatality; strong public trust

COVID-19 DETECTION TECHNIQUES

1. RT-PCR (Reverse Transcription Polymerase Chain Reaction)

RT-PCR is considered the gold standard for detecting SARS-CoV-2 due to its high sensitivity and specificity. It involves converting viral RNA into DNA and amplifying it to detect infection accurately. Typically, samples are taken from nasal or throat swabs and processed in laboratories. Results are usually available within 4 to 8 hours. Despite its precision, it is time-consuming and requires trained personnel and equipment. It is most effective in the early stages of infection [26]. Studies have consistently supported RT-PCR's role in confirming COVID-19 diagnosis. However, its limitations in resource-poor settings remain a challenge.

2. Rapid Antigen Test

This test detects viral proteins from nasal or throat swabs, providing results within 15–30 minutes. It is commonly used for quick screening, especially in mass testing scenarios like airports and schools. Though less sensitive than RT-PCR, it is effective in identifying highly infectious individuals [27]. The rapidity of results makes it useful in emergency and high-volume settings.

However, due to a higher false negative rate, follow-up RT-PCR tests are often recommended. Its affordability and minimal equipment requirements increase its accessibility. Antigen tests are particularly helpful when immediate isolation decisions are needed.

3. CBNAAT (Cartridge-Based Nucleic Acid Amplification Test)

CBNAAT offers a quicker, automated version of RT-PCR using a closed cartridge system. It performs sample preparation and detection in a single device, reducing contamination risk and user error [28]. Results can be obtained in 1–2 hours, making it suitable for rapid diagnostic settings. This method is especially helpful in semi-urban hospitals and mobile testing labs. Its accuracy is comparable to conventional RT-PCR tests. CBNAAT has proven vital in India and other developing regions for its portability. It bridges the gap between high-precision testing and field applicability. WHO and ICMR have endorsed its usage.

4. TRUENAT

Truenat is a chip-based RT-PCR alternative tailored for point-of-care diagnostics, particularly in resource-limited settings. It uses portable battery-powered devices to amplify viral RNA from nasal swabs. The test delivers results in 60–90 minutes [29]. Approved by the Indian Council of Medical Research, Truenat has played a major role in expanding testing access in rural areas. Originally developed for tuberculosis detection, its adaptation for COVID-19 was rapid. While slightly less sensitive than lab-based RT-PCR, its ease of use compensates well. It allows for real-time diagnosis with minimal infrastructure. Its modular design ensures flexibility in deployment.

5. Chest CT Scan

CT imaging supports COVID-19 diagnosis by revealing lung abnormalities such as ground-glass opacities and bilateral infiltrates. While not a primary detection method, it’s particularly helpful in symptomatic patients with negative RT-PCR results [30]. CT scans provide instant visualization of lung involvement, aiding in triage and treatment decisions. It is most valuable in moderate to severe cases with respiratory distress. However, specificity is low as similar patterns can be seen in other pneumonias. It involves radiation exposure, limiting its frequent use. CT findings can help predict disease progression. Radiologists often use CT alongside clinical and lab data.

6. Serological (Antibody) Tests

These tests detect IgM and IgG antibodies in blood, indicating past exposure rather than active infection. They are not effective for early diagnosis as antibodies typically develop after several days or weeks [31]. Serology is mainly used in population-level surveillance and research. It helps assess the spread of infection and community-level immunity. The test is quick and inexpensive, using standard ELISA or rapid formats. False negatives may occur in immunocompromised patients. Despite their limitations, antibody tests assist in understanding vaccine responses. They are essential tools in longitudinal epidemiological studies.

7. LAMP (Loop-Mediated Isothermal Amplification)

LAMP is a molecular technique that amplifies viral RNA at a constant temperature, simplifying the detection process. Unlike RT-PCR, it doesn't require thermal cycling, making it suitable for portable testing devices [32]. It delivers results within 30–60 minutes and is cost-effective. LAMP is ideal for rapid screening in field or rural settings. Its sensitivity is generally high, though slightly lower than RT-PCR. The technology is easy to implement with minimal training. It is gaining traction for decentralized diagnostic strategies. Research supports its integration into low-resource pandemic responses.

8. CRISPR-Based Detection

This innovative method uses CRISPR-Cas systems to identify specific sequences of SARS-CoV-2 RNA. Enzymes like Cas12 or Cas13 are programmed to target and cut viral RNA, producing a detectable signal [33]. CRISPR-based tests offer high specificity and fast results, often within an hour. They do not require complex equipment, enabling portability. Tests like SHERLOCK and DETECTR are under development or early deployment. Their adaptability makes them promising for emerging variants. This technology may revolutionize molecular diagnostics. Research is ongoing to optimize its use in clinical and remote settings.

Table 2 – COVID-19 Recognition Technique

Name	Authors	Main Idea	Problems	Rate of Recognition
RT-PCR	Corman et al. [26]	Detects viral RNA using real-time PCR technology	Requires lab setup, expensive, longer turnaround time	High (~95%)
Rapid Antigen Test	Scohy et al. [27]	Detects viral proteins; suitable for mass screening	Lower sensitivity, false negatives in early infection	Moderate (~60–70%)
CBNAAT	ICMR [28]	Cartridge-based RT-PCR; automated and fast	Requires specific cartridges and device; cost is	High (~90–95%)

			higher than rapid tests	
Truenat	ICMR [29]	Chip-based RT-PCR for point-of-care use	Slightly lower sensitivity than standard RT-PCR	High (~85–90%)
Chest CT Scan	Fang et al. [30]	Detects COVID-19 pneumonia via lung imaging	Non-specific findings, exposure to radiation	Moderate (~80%)
Serological Antibody Test	Long et al. [31]	Detects IgG/IgM antibodies post-infection	Cannot detect early infection, dependent on immune response timing	Variable (50–90%)
LAMP	Notomi et al. [32]	Isothermal amplification; rapid and equipment-light	Less sensitive than RT-PCR, prone to contamination	High (~85–95%)
CRISPR-Based Detection	Broughton et al. [33]	Uses CRISPR-Cas12/Cas13 to detect SARS-CoV-2 RNA	Still under development, limited large-scale validation	High (>90%)

4. POST-COVID HEALTH PROBLEMS AND PHYSIOLOGICAL EFFECTS

As global recovery from COVID-19 advances, attention has increasingly turned to the long-term consequences of SARS-CoV-2 infection. Many individuals, regardless of initial disease severity, have reported persistent symptoms lasting weeks or even months after recovery. This condition is commonly referred to as "long COVID" or post-acute sequelae of SARS-CoV-2 infection (PASC).

Numerous studies have identified that long COVID affects multiple organ systems. The most frequently reported symptoms include fatigue, shortness of breath, cognitive dysfunction ("brain fog"), and chest pain. These symptoms significantly impact daily functioning and quality of life. A study by the UK Office for National Statistics found that approximately 1 in 10 individuals infected with COVID-19 experience symptoms lasting longer than 12 weeks [54].

The cardiovascular system is particularly vulnerable. Patients have shown increased risks for myocarditis, heart palpitations, and clotting disorders even months after acute infection [55]. Respiratory issues, such as chronic cough and reduced lung function, have also persisted in many patients, especially those who suffered from pneumonia or ARDS during their illness [56].

Neurological complications range from headaches and sleep disturbances to more serious concerns like memory loss and difficulty concentrating. Several case studies have linked COVID-19 with increased risks of stroke and encephalopathy [57]. Additionally, some recovered patients develop mental health disorders, including depression, anxiety, and post-traumatic stress disorder, influenced by both physiological and social factors during the pandemic [58].

Musculoskeletal symptoms such as muscle weakness, joint pain, and general malaise are commonly reported and are believed to be linked to post-viral fatigue syndromes. These symptoms are particularly debilitating in older adults and those who required prolonged hospitalization or intensive care [59].

Digestive system effects, including nausea, diarrhea, and loss of appetite, may also persist after recovery. Moreover, liver and kidney abnormalities have been observed in patients who developed complications during the acute phase [60].

These post-COVID complications demonstrate the need for long-term monitoring and interdisciplinary care models to address physical, mental, and social well-being in recovered patients. Emerging rehabilitation protocols focus on respiratory therapy, physical activity, psychological support, and nutritional care.

5. CONCLUSION

This paper provides a review of well-known research on the health effects of COVID-19. The analysis of the pandemic has been structured across multiple stages: the origin and spread of the virus, preventive measures, diagnostic techniques, and the health impact across various populations and countries. Diagnostic methods such as RT-PCR, antigen tests, and CRISPR-based technologies have played a critical role in early detection and containment of the virus. Each method contributes to improving the speed, reach, and accuracy of COVID-19 testing.

In the health impact analysis, particular emphasis has been placed on post-COVID complications that continue to affect individuals long after recovery. Conditions such as long COVID, which involve persistent symptoms including fatigue, respiratory distress, and cognitive dysfunction, have been shown to significantly affect the quality of life. These conditions require ongoing monitoring and care strategies.

The pandemic has revealed gaps in public health systems globally, especially in developing countries, and emphasized the importance of equitable access to healthcare services. By compiling findings on regional outcomes, especially in Asia, the review demonstrates the disparities in infection control, vaccine access, and healthcare response.

Post-COVID health care must be interdisciplinary, addressing both physical and psychological consequences. Future work includes establishing standardized rehabilitation protocols and integrating post-COVID management into national health policies. The study highlights the importance of continued research, surveillance, and long-term policy planning to address these evolving challenges.

References

1. P. Zhou et al., “A pneumonia outbreak associated with a new coronavirus of probable bat origin,” Nature, vol. 579, pp. 270–273, 2020.
2. World Health Organization, “WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020,” 2020. [Online]. Available: https://www.who.int
3. R. Lu et al., “Genomic characterisation and epidemiology of 2019 novel coronavirus,” The Lancet, vol. 395, no. 10224, pp. 565–574, 2020.
4. K. G. Andersen et al., “The proximal origin of SARS-CoV-2,” Nature Medicine, vol. 26, pp. 450–452, 2020.
5. W. J. Guan et al., “Clinical characteristics of coronavirus disease 2019 in China,” N. Engl. J. Med., vol. 382, pp. 1708–1720, 2020.
6. J. Yang et al., “Prevalence of comorbidities in COVID-19 infection: A systematic review and meta-analysis,” Int. J. Infect. Dis., vol. 94, pp. 91–95, 2020.
7. S. Hsiang et al., “The effect of large-scale anti-contagion policies on the COVID-19 pandemic,” Nature, vol. 584, pp. 262–267, 2020.
8. N. Ferguson et al., “Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand,” Imperial College London, 2020.
9. A. Carfì, R. Bernabei, and F. Landi, “Persistent symptoms in patients after acute COVID-19,” JAMA, vol. 324, no. 6, pp. 603–605, 2020.
10. A. Nalbandian et al., “Post-acute COVID-19 syndrome,” Nature Medicine, vol. 27, no. 4, pp. 601–615, 2021.
11. C. H. Sudre et al., “Attributes and predictors of long COVID,” Nature Medicine, vol. 27, no. 4, pp. 626–631, 2021.
12. N. J. Lambert et al., “COVID-19 ‘long hauler’ symptoms survey report,” Indiana University School of Medicine, 2021.
13. H. E. Davis et al., “Characterizing long COVID in an international cohort,” EClinicalMedicine, vol. 38, p. 101019, 2021.
14. M. Taquet et al., “Neurological and psychiatric outcomes in COVID-19 survivors,” The Lancet Psychiatry, vol. 8, no. 5, pp. 416–427, 2021.

15. A. V. Raveendran et al., "Long COVID: An overview," Diabetes Metab. Syndr. Clin. Res. Rev., vol. 15, no. 3, pp. 869–875, 2021.
16. T. Greenhalgh et al., "Management of post-acute COVID-19 in primary care," BMJ, vol. 370, p. m3026, 2020.
17. P. Zimmermann and N. Curtis, "Coronavirus infections in children including COVID-19," Pediatr. Infect. Dis. J., vol. 39, no. 5, pp. 355–368, 2020.
18. S. S. Bhopal and R. Bhopal, "Sex differential in COVID-19 mortality varies markedly by age," The Lancet, vol. 396, no. 10250, pp. 532–533, 2020.
19. L. R. Feldstein et al., "Multisystem inflammatory syndrome in U.S. children and adolescents," N. Engl. J. Med., vol. 383, pp. 334–346, 2020.
20. F. P. Polack et al., "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine," N. Engl. J. Med., vol. 383, pp. 2603–2615, 2020.
21. L. R. Baden et al., "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine," N. Engl. J. Med., vol. 384, pp. 403–416, 2021.
22. N. Dagan et al., "BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting," N. Engl. J. Med., vol. 384, no. 15, pp. 1412–1423, 2021.
23. M. G. Thompson et al., "Interim estimates of vaccine effectiveness," MMWR, vol. 70, no. 13, pp. 495–500, 2021.
24. E. Callaway, "Delta coronavirus variant: Scientists brace for impact," Nature, vol. 595, p. 17–18, 2021.
25. N. E. MacDonald, "Vaccine hesitancy: Definition, scope and determinants," Vaccine, vol. 33, no. 34, pp. 4161–4164, 2015.
26. V. M. Corman et al., "Detection of 2019 novel coronavirus by real-time RT-PCR," Euro Surveill., vol. 25, no. 3, 2020.
27. A. Scohy et al., "Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis," J. Clin. Virol., vol. 129, 2020.
28. Indian Council of Medical Research, "Advisory on use of CBNAAT test for COVID-19," ICMR, 2020.
29. Indian Council of Medical Research, "Truenat tests for COVID-19 diagnosis," ICMR, 2020.
30. Y. Fang et al., "Sensitivity of chest CT for COVID-19: comparison to RT-PCR," Radiology, vol. 296, no. 2, 2020.
31. Q. X. Long et al., "Antibody responses to SARS-CoV-2 in patients with COVID-19," Nat. Med., vol. 26, no. 6, 2020.
32. T. Notomi et al., "Loop-mediated isothermal amplification of DNA," Nucleic Acids Res., vol. 28, no. 12, 2000.
33. J. P. Broughton et al., "CRISPR–Cas12-based detection of SARS-CoV-2," Nat. Biotechnol., vol. 38, no. 7, 2020.
34. World Health Organization, "Coronavirus Dashboard – Global Summary," WHO, 2023.

35. Asian Development Bank, COVID-19 and Resilience in Asia, 2022.
36. Ministry of Health and Family Welfare, India, “COVID-19 Daily Bulletin,” MoHFW, 2023.
37. The Lancet, “India’s COVID-19 vaccine rollout: challenges and solutions,” The Lancet, vol. 397, no. 10288, 2021.
38. Y. Huang, “China’s Fight Against COVID-19,” Council on Foreign Relations, 2020.
39. NPR, “China’s sudden end to Zero-COVID sparks chaos,” 2022.
40. The Economist, “Tracking the Real COVID Death Toll in China,” 2023.
41. Ministry of Health, Indonesia, “COVID-19 Situation Report,” 2023.
42. Reuters, “Philippines battles record COVID-19 cases amid ICU shortages,” 2021.
43. Korea Centers for Disease Control (KCDC), “COVID-19 Response Overview,” 2022.
44. Nikkei Asia, “Japan’s Elder Vaccination Success,” 2021.
45. The BMJ, “Public Health Measures and Compliance in Asia,” Brit. Med. J., 2020.
46. Dawn News, “Pakistan’s COVID testing challenges and responses,” 2023.
47. UNICEF, “Supporting Bangladesh’s Pandemic Recovery,” 2022.
48. Vietnam News Agency, “COVID-19 Resurgence Timeline,” 2023.
49. WHO Vietnam Office, “Country Situation Report,” 2023.
50. WHO Eastern Mediterranean Region, “Iran: Health Systems Under Pressure,” 2023.
51. Ministry of Health, Malaysia, “COVID-19 National Summary,” 2023.
52. Singapore Ministry of Health, “COVID-19 Dashboard,” 2023.
53. The Straits Times, “How Singapore Managed COVID-19: A Timeline,” 2023.
54. Office for National Statistics (UK), “Prevalence of ongoing symptoms following coronavirus (COVID-19) infection,” 2021.
55. Y. Xie et al., “Long-term cardiovascular outcomes of COVID-19,” Nature Medicine, vol. 28, no. 3, pp. 583–590, 2022.
56. X. Mo et al., “Abnormal pulmonary function in COVID-19 patients at time of hospital discharge,” Eur. Respir. J., vol. 55, no. 6, p. 2001217, 2020.
57. M. Taquet et al., “6-month neurological and psychiatric outcomes in COVID-19 survivors,” The Lancet Psychiatry, vol. 8, no. 5, pp. 416–427, 2021.
58. J. P. Rogers et al., “Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections,” The Lancet Psychiatry, vol. 7, no. 7, pp. 611–627, 2020.
59. A. Carfi et al., “Persistent symptoms in patients after acute COVID-19,” JAMA, vol. 324, no. 6, pp. 603–605, 2020.
60. L. Chan et al., “AKI in hospitalized patients with COVID-19,” J. Am. Soc. Nephrol., vol. 32, no. 1, pp. 151–160, 2021.